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is organised at national level, in close collaboration between ASN and 
radiotherapy professionals, leading to the publication of newsletters 
about the safety of patients. 
Taking into account one of the main findings of the international 
conference on Modern Radiotherapy, organised in 2009, by ASN, in 
Versailles (France), the European Commission decided to strengthen 
the European Basic Safety Standard introducing new requirements 
related to events reporting and risk analysis, and to launch the 
ACCIRAD project led by the Greater Poland Cancer Centre (GPCC, 
Poland)[1], following the goal to issue an European guidance on these 
topics in 2013. A general questionnaire sent to member states in 2012 
showed that more than half EU countries have already implemented in 
their legal system a requirement for risk analysis in radiotherapy, and 
classification, recording and reporting of adverse events and near 
misses. However, despite 15 years passed since 1997, in many EU 
countries the requirement for a legal framework regarding risk 
analysis and event’s classification, recording and reporting systems 
was not addressed and the practical implementation of the systems 
was still incomplete.A 2nd questionnaire, still being analysed, should 
allow to identify pertinent risk analysis methodologies used by 
radiotherapy centres and also good practices for event’s 
classification. On this basis, recommendations will be prepared by the 
ACCIRAD consortium to be included in the European guidance. The 
first results of these on going works will be presented at the  Geneva 
ESTRO conference in April 2013. 
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Characterising the dose-volume response of normal tissue structures is 
an important part of optimising radiotherapy treatment planning. 
However, understanding how the dose-distribution to a structure is 
related to outcome is confounded by co-morbidities and combinations 
of treatments as well as incomplete and inconsistent data.  One 
approach to this challenge is Machine Learning.  Machine learning 
describes models which learn from examples of a specific data type 
without a priori information about the relationship between the data.  
When both input variables and the corresponding outcome data are 
available, this known as supervised learning.  Once the relationship 
has been inferred it is possible to make prediction for previously 
unseen cases. 
The published literature on the use of machine learning approaches to 
model dose-volume effects utilise different algorithms.  Two 
commonly used supervised learning approaches are Artificial Neural 
Networks and Support Vector Machines. 
Artificial Neural Networks (ANN) are a (simplified) mathematical 
analogy of learning in the brain.  An ANN is trained by presenting 
example datasets to the network.  Input variables are propagated 
through a network of interconnected nodes and compared to the 
known outcome.  The weights of the connections between the nodes 
are altered iteratively so that the outcome is predicted correctly from 
the input data. 
Support vector machines (SVM) are used for dichotomised outcomes 
e.g. toxicity/no toxicity.  Separation between the two possible classes 
is achieved by translating the input variables in to a high-dimensional 
feature space where a boundary is derived to maximise the separation 
between the classes.    
An important consideration when developing a machine learning-based 
model is how to represent the input data.  This issue is not unique to 
machine learning and is also relevant to conventional statistical 
approaches.   When trying to predict radiation-induced toxicity the 
dose distribution to relevant structures need to be included. 
 Generally this is achieved by using summary measures such maximum 
dose and mean dose to the structure.  The dose-volume histogram can 
be reduced to a summary measure such as Equivalent Uniform Dose 
(EUD).  Often sequential variables describing the volume of the 
structure receiving a specified dose eg V5, V10, V15 etc are included.  
 A more detailed approach is to include a spatial description of the 
dose.  These dosimetric features will be combined with clinical 
information and information regarding other therapies such as 
chemotherapy. 
A successful model will be able to make predictions for previously 
unseen data.  Cross validation, where models are built on subsets of 
available data and tested and validated on independent samples, can 
ensure the ability of a model to generalise.  The effect of each 
variable on the ability of a model to make accurate predictions can be 
assessed with methods such as “leave one out” which as suggested 
repeats the process without a variable and assess the effect. 
This presentation will provide an overview of published literature on 
the modelling of dose-volume effects using machine learning.   A 
worked example of both ANN and SVM approaches to predict acute 
toxicity following head and neck radiotherapy will be used to 
demonstrate methodology.  The results will also be compared to a 
conventional multivariable analysis.   
Relatively little has been published on the use of machine learning 
approaches to the modelling of dose-volume effects.  However, they 
provide a complementary alternative to conventional statistical 
techniques. Consequently there is potential to further our 
understanding of the relationship between the dose distribution to a 
normal structure and corresponding radiation-induced toxicity. 
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It is well known that the risk of radio-induced toxicity increases when 
higher doses and larger volumes are involved in the irradiation and, in 
the last years, some consistent results have been published on the 
possible estimation of normal tissue complication probability (NTCP) 
for a number of organs-at-risk. The widespread method used for such 
calculations is based on a sigmoid dose-response curve coupled to 
reduction of the whole dose-volume histogram into one parameter 
(such as the equivalent uniform dose).  
NTCP models with their prediction based only on dosimetric variables 
can be used in treatment planning and can act as a baseline 
reference.  
On the other hand, it is becoming clearer that radiation-related side 
effects are also correlated to a number of patient-related factors. 
With the advent of newer radiotherapy technologies, which allow 
steep gradients and minimization of doses to normal tissues, there is 
an increased interest in understanding clinical/genetic risk factors 
that might enhance patient radio-sensitivity and to develop NTCP 
models which might include these variables in order to achieve better 
normal tissue complication predictions.  
Some recently published studies have shown that current NTCP models 
can be improved by incorporating clinical risk factors into model 
formulation. Overview of published results will be presented. 
A further important step is the inclusion of molecular/genetic 
predictors into NTCP models. This issue is still at a very primitive 
stage  and should be elucidated because, given the same set of 
clinical/dosimetric factors, patient-to patient variability in normal 
tissue response to radiation has been widely recognized in clinical 
practice, suggesting that this phenomenon might be, at least in part, 
genetically driven. 
In this presentation data on molecular/genetic markers influencing 
radio-induced toxicity are presented, together with the first findings 
supporting the hypothesis that a genetically determined dose–response 
relationship is possible and could be used to predict the probability of 
side effects associated with radiotherapy and serve as a rational basis 
for individualized radiation dose prescriptions. 
The future lies in these multi-factorial prediction models: a great 
effort has to be done to collect reliable detailed prospective data for 
the development of NTCP models with the inclusion of predisposing 
clinical/geneticfeatures for normal tissues involved in radiotherapy. 
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Trismus, which results in difficulty, restriction or pain when opening 
the mouth (CTCAE), is a common complication in head and neck 
cancer patients following radiotherapy and leads to degradation in 
quality of life. There are few studies that have addressed radiation 
induced trismus. However, the main cause remains poorly understood. 
Studies have attributed trismus to the irradiation of a range of organs 
at risk (OAR) such as the mastication muscles, the temporomandibular 
joint (TMJ), and pterygoid plate among others.  
